Generic Gablofen Availability
GABLOFEN (baclofen - injectable;intrathecal)
Manufacturer: MALLINCKRODT INC
Approval date: November 19, 2010
Strength(s): 0.05MG/ML [AP], 0.5MG/ML [AP], 2MG/ML [AP]
Manufacturer: MALLINCKRODT INC
Approval date: June 22, 2012
Has a generic version of Gablofen been approved?
No. There is currently no therapeutically equivalent version of Gablofen available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gablofen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Gablofen.
- Gablofen Consumer Information (Drugs.com)
- Gablofen Consumer Information (Wolters Kluwer)
- Gablofen Advanced Consumer Information (Micromedex®)
- Baclofen Consumer Information (Drugs.com)
- Baclofen Consumer Information (Wolters Kluwer)
- Baclofen tablets Consumer Information (Wolters Kluwer)
- Baclofen Consumer Information (Cerner Multum)
- Baclofen Advanced Consumer Information (Micromedex®)
- Baclofen Intrathecal Advanced Consumer Information (Micromedex®)
- Baclofen AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|AP||Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.|